National Cancer Institute to Test Serenex Compound
January 25th, 2008
The compound has shown “exceptional efficacy” in preclinical studies, according to Serenex Chief Executive Officer Richard Kent. The work with the NCI could lead to the launch of clinical trials in patients with lung cancer, Kent added.